Trials / Completed
CompletedNCT01255657
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
A Phase 1 Study of ABT-806 in Subjects With Advanced Solid Tumor Types Likely to Either Overexpress Wild-Type Epidermal Growth Factor Receptor (EGFR) or to Express Variant III Mutant EGFR
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-806 | ABT-806 will be administered by intravenous infusion. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2010-12-07
- Last updated
- 2017-11-21
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01255657. Inclusion in this directory is not an endorsement.